Stereotaxis

Stereotaxis has completed the acquisition of Robocath and is integrating its team and the R-One robotic system, which is CE- and NMPA-certified and used in Europe and China. Clinical studies report a technical success rate of over 98% without major cardiovascular events. The transaction includes contingent payments tied to regulatory and commercial milestones; financial details were not disclosed. Stereotaxis most recently reported annual revenue of USD 31.2 million while remaining unprofitable; market capitalization is USD 175.93 million, analyst targets range from USD 3.50 to 5.00, while the current share price is around USD 1.80. » More on de.investing.com

At Stereotaxis’s annual general meeting, David Benfer, Dr. Arun Menawat and Dr. Myriam Curet were elected to the board through 2029, Ernst & Young was confirmed as the independent auditor for 2026, and executive compensation was approved in an advisory vote. The meeting was quorate with about 65.3% of the voting capital. Separately, Stereotaxis reported Q1 2026 results that missed market expectations (EPS -$0.06; revenue $6.3 million), triggering a share price decline. » More on de.investing.com

Stereotaxis reported Q1 2026 EPS of -$0.06 (forecast -$0.05) and revenue of $6.3m versus expected $8.72m. Revenue fell 15.9% year‑on‑year, weighed down by the strategic move away from Johnson & Johnson’s catheter ecosystem and production bottlenecks for new products. Management points to important regulatory approvals and plans to ramp production to 500 MAGiC catheters per month by the end of 2026, but expects continued short‑term revenue volatility. The stock fell about 3.7% after the results to $1.81 and is approaching its 52‑week low. » More on de.investing.com

Stereotaxis will open the books for the quarter ending 31.12.2025 on 09.03.2026. Four analysts on average forecast EPS of -0.063 USD versus -0.090 USD a year ago. Five analysts expect revenue to rise 43.22% to 9.1 Mio. USD (prior year 6.3 Mio. USD). For the fiscal year, analysts see an average loss per share of -0.255 USD and revenue of 32.8 Mio. USD versus 26.9 Mio. in the prior year. » More on finanzen.net

Stereotaxis’s stock jumped 8.3% after the announcement of FDA approval for the interventional magnetic ablation catheter MAGiC. The catheter enables precise, computer-controlled magnetic navigation for cardiac ablation procedures and is indicated for electrophysiological mapping, delivery of diagnostic stimulations, and endocardial lesions. Stereotaxis sees the approval as a milestone toward expanding access to ablation therapy for complex and previously underserved patient groups. » More on de.investing.com